Disclosed is the use of nanoparticles comprising paclitaxel and an albumin and a platinum-based agent such as carboplatin, in the manufacture of a medicament for treatment of non-small cell lung cancer (NSCLC) in an individual, wherein treatment is based upon the NSCLC being squamous cellular carcinoma, and wherein the medicament is formulated for separate, sequential or simultaneous administration of (a) and (b).
